Biocorrx INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
BICX
Biocorrx INCBioCorRx Inc. announced the resignation of director Kate Beebe DeVarney, Ph.D., effective August 31, 2026, with no stated disagreements.
OID
BICX
Biocorrx INCBioCorRx Inc. has acquired a 12.15% stake in its subsidiary, BioCorRx Pharmaceuticals, from key executives and directors in a stock-for-stock exchange.
OID
BICX
Biocorrx INCBioCorRx Inc. has entered into a Securities Purchase Agreement to raise $350,000 by issuing common stock and warrants to accredited investors.
OID
BICX
Biocorrx INCBioCorRx Pharmaceuticals Inc. acquires Lucemyra, an FDA-approved medication for opioid withdrawal, from USWM, LLC to expand its addiction treatment offerings.
OID
BICX
Biocorrx INCBioCorRx Inc. has replaced its independent auditor, Marcum LLP, with M&K CPAS, PLLC, effective July 8, 2024.
OID
BICX
Biocorrx INCBioCorRx Inc. reports the resignation of two board members, Brady Granier and Harsha Murthy, effective March 31, 2024, and April 2, 2024, respectively.